Kyowa Hakko Bio Co., Ltd, an international health ingredients manufacturer and world leader in the development, manufacturing, and marketing of pharmaceuticals, nutraceuticals and food products announced Cognizin® Citicoline may notably improve composite memory, specifically episodic memory.
The study, titled aimed to investigate the effects of citicoline on memory in healthy elderly populations with age-associated memory impairment (AAMI). A total of 100 healthy men and women between ages 50 and 85 were evaluated as a part of this randomized, double-blind, placebo-controlled trial*1 during an intervention period of twelve weeks. Participants were randomized to receive either a 500 mg/d dosage of citicoline or a placebo, with memory functions assessed at baseline and at the end of the intervention using standardized computerized tests. Between-group analysis indicated that the changes from baseline scores were statistically significantly different between test groups for Paired Associates, which was the outcome for episodic memory, and Composite Memory which was the outcome for overall memory, whereby the citicoline group demonstrated greater improvements in these tests compared with the placebo group. We did not observe any serious adverse events following daily consumption of citicoline for 12 weeks.
*1A testing methodology used in clinical trials in which participants are randomly divided into groups to receive the placebo or the actual-active ingredient, and which group is which is unknown until the trial is completed.
The study concluded that “dietary supplementation of citicoline for 12-week improved overall memory performance, especially episodic memory, in healthy older males and females with AAMI. The findings suggest that regular consumption of citicoline may be safe and potentially beneficial against memory loss due to aging.”
Eri Nakazaki, Ph.D, Lead Researcher at KIRIN Central Research Institute where is R&D division of Kyowa Hakko Bio’s parent company explains that, "Citicoline is a potent brain-health nutrient found in cells of the body and is especially vital to brain health and the formation of phospholipids. Citicoline also increases an important substance in the brain called phosphatidylcholine that supports healthy brain function.*" Cognizin® is a branded form of Citicoline that has been clinically studied to support mental energy, focus, and attention*. "The data from this analysis is very encouraging that regular consumption, 500mg/d, of Cognizin® citicoline may be safe and potentially beneficial against memory loss due to aging."
This study contributes to the growing body of evidence that demonstrates the clear value of Cognizin®, featured in over 200 products globally. Unlike other ingredients, Cognizin® isn’t chemically synthesized, and is made by Kyowa Hakko’s innovative fermentation process to deliver top-quality and purity, while being vegetarian, allergen-free and self-affirmed GRAS.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
About Cognizin® Citicoline
Cognizin® Citicoline, manufactured by Kyowa Hakko Bio Co., Ltd., is a clinically studied and branded form of Citicoline, a natural substance made endogenously in the body and especially vital to brain health.* Citicoline is a potent brain-health nutrient. A proprietary form of citicoline, Cognizin® has been clinically studied to support mental energy, focus, attention, and recall. Cognizin® is manufactured through a fermentation process to yield high quality and high purity. Cognizin® is also highly stable, GRAS, ultra-pure and allergen-free. For more information on Cognizin®, visit Cognizin.com.
About Kyowa Hakko USA
Kyowa Hakko USA is the North & South American office for Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing, and marketing of pharmaceuticals, nutraceuticals and food products. For more information visit Kyowa-USA.com.
About Kirin Holdings
Kirin Holdings Company, Limited is an international company that operates in the Food & Beverages domain (Food & Beverages businesses), Pharmaceuticals domain (Pharmaceuticals businesses), and Health Science domain (Health Science business), both in Japan and across the globe.
Kirin Holdings can trace its roots to Japan Brewery which was established in 1885. Japan Brewery became Kirin Brewery in 1907. Since then, the company expanded its business with fermentation and biotechnology as its core technologies, and entered the pharmaceutical business in the 1980s, all of which continue to be global growth centers. In 2007, Kirin Holdings was established as a pure holding company and is currently focusing on boosting its Health Science domain.
Under the Kirin Group Vision 2027 (KV 2027), a long-term management plan launched in 2019, the Kirin Group aims to become “A global leader in CSV*, creating value across our world of Food & Beverages to Pharmaceuticals.” Going forward, the Kirin Group will continue to leverage its strengths to create both social and economic value through its businesses, with the aim of achieving sustainable growth in corporate value.